Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23797050 | 0.87 | ALOX15 (0.50) | ALOX15GFERADAM17RAB9AALDH1A1 | |
| SCHEMBL22281426 | 0.84 | GSK3B (0.61) | ALOX15ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL19642631 | 0.84 | ATM (0.54) | ALOX15GFERADAM17RAB9AALDH1A1 | |
| SCHEMBL22728863 | 0.83 | ALOX15 (0.47) | ALOX15GFERADAM17RAB9AALDH1A1 | |
| SCHEMBL19660150 | 0.81 | L3MBTL1 (0.50) | ALDH1A1PKMHTTKMT2AL3MBTL1 | |
| SCHEMBL10455298 | 0.81 | HDAC3 (0.54) | ALOX15GFERADAM17RAB9AALDH1A1 | |
| SCHEMBL19660200 | 0.81 | HDAC3 (0.48) | RAB9AALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL19659999 | 0.79 | L3MBTL1 (0.60) | RAB9AALDH1A1PKMHTTKMT2A | |
| SCHEMBL19660210 | 0.78 | KMT2A (0.49) | RAB9AALDH1A1PKMHTTKMT2A | |
| SCHEMBL19660154 | 0.78 | GSK3B (0.57) | ALOX15RAB9AALDH1A1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| CN-116554152-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116531380-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-110678459-B | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-109863140-B | 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide | 拜耳医药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-3464248-B1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-22 | — | — | US | disclosed |
| EP-3580211-B1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AG (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| CN-110678459-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2020-01-10 | — | — | CN | disclosed |
| WO-2017202816-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | ALOX15 763/4885GFER 981/4885ADAM17 4645/4885 |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | AHR, HRH2, HRH4 | ALOX15 383/4885GFER 2128/4885ADAM17 3920/4885 |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | AHR, ARNT, HRH2 | ALOX15 539/4885GFER 2331/4885ADAM17 4134/4885 |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | ALOX15 539/4885GFER 2331/4885ADAM17 4134/4885 |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | AHR, HRH2, HRH4 | ALOX15 383/4885GFER 2128/4885ADAM17 3920/4885 |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | ALOX15 547/4885GFER 2318/4885ADAM17 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.